Company news

Crescent Biopharma, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001

October 15, 2026

Crescent Biopharma Announces Grants of Inducement Awards

October 6, 2026

Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors

October 5, 2026

Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

July 29, 2026

Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

July 16, 2026

Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants

July 14, 2026

Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants

July 14, 2026

Crescent Biopharma to Present at June Investor Conferences

June 2, 2026

Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

May 21, 2026

Crescent Biopharma to Present at May Investor Conferences

May 6, 2026

Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights

April 29, 2026

Crescent Biopharma Announces Grants of Inducement Awards

March 26, 2026

Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

February 25, 2026

Crescent Biopharma to Present at March Investor Conferences

February 23, 2026

Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors

February 17, 2026

Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

February 5, 2026

Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors

January 4, 2026

Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics

December 4, 2025

Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors

December 3, 2025

Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

November 6, 2025

Crescent Biopharma to Present at November Investor Conferences

November 5, 2025

Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

November 3, 2025

Crescent Biopharma to Present at September Investor Conferences

August 28, 2025

Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

July 30, 2025

Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer

July 8, 2025

Calls

The 5 newest of 13 calls. Every call is listed under its year.

Decks

The 5 newest of 6 decks. Every deck is listed under its year.